Join Growin Stock Community!

Aditxt, inc.ADTX.US Overview

US StockHealthcare
(No presentation for ADTX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ADTX AI Insights

ADTX Overall Performance

ADTX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ADTX Recent Performance

-4.92%

Aditxt, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ADTX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ADTX Key Information

ADTX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ADTX Profile

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

Price of ADTX

ADTX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ADTX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1963.24
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
136.58
PB Ratio
0.11
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-1111.24%
Net Margin
-710498.74%
Revenue Growth (YoY)
-97.20%
Profit Growth (YoY)
89.52%
3-Year Revenue Growth
-86.77%
3-Year Profit Growth
-57.11%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1963.24
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
136.58
PB Ratio
0.11
Price-to-FCF
-
Gross Margin
-1111.24%
Net Margin
-710498.74%
Revenue Growth (YoY)
-97.20%
Profit Growth (YoY)
89.52%
3-Year Revenue Growth
-86.77%
3-Year Profit Growth
-57.11%
  • When is ADTX's latest earnings report released?

    The most recent financial report for Aditxt, inc. (ADTX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ADTX's short-term business performance and financial health. For the latest updates on ADTX's earnings releases, visit this page regularly.

  • What is the operating profit of ADTX?

    According to the latest financial report, Aditxt, inc. (ADTX) reported an Operating Profit of -3.14M with an Operating Margin of -419,870.32% this period, representing a growth of 33.19% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ADTX's revenue growth?

    In the latest financial report, Aditxt, inc. (ADTX) announced revenue of 748, with a Year-Over-Year growth rate of -89.09%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does ADTX have?

    At the end of the period, Aditxt, inc. (ADTX) held Total Cash and Cash Equivalents of 407.74K, accounting for 0.03 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ADTX go with three margins increasing?

    In the latest report, Aditxt, inc. (ADTX) did not achieve the “three margins increasing” benchmark, with a gross margin of 2.1%%, operating margin of -419,870.32%%, and net margin of -3,214,626.3%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ADTX's profit trajectory and future growth potential.

  • Is ADTX's EPS continuing to grow?

    According to the past four quarterly reports, Aditxt, inc. (ADTX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -548.78. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ADTX?

    Aditxt, inc. (ADTX)'s Free Cash Flow (FCF) for the period is -2.34M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 0.84% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ADTX?

    The latest valuation data shows Aditxt, inc. (ADTX) has a Price-To-Earnings (PE) ratio of -0.05 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.